动脉内注射NEO100增强嵌合抗原受体T细胞脑内递送及治疗活性:中枢神经系统淋巴瘤小鼠模型研究
研究在中枢神经系统淋巴瘤小鼠模型中,先经动脉内注射0.3% NEO100开放血脑屏障,再静脉输注CD19靶向CAR T细胞。结果显示NEO100组脑肿瘤区可检出CAR T细胞,全部小鼠存活至200天实验终止,而未经NEO100预处理组3只死亡、2只长期存活。作者认为该一次性干预可能具有治愈性。
要点
- 动脉内NEO100开放血脑屏障后,静脉输注的CD19 CAR T细胞可进入脑肿瘤区域。
- 接受NEO100联合CAR T细胞的小鼠全部存活至200天实验终止,未治疗对照全部3周内死亡。
- 未经NEO100预处理的CAR T细胞组3只3周内死亡、2只长期存活。
核心结论
- 动脉内NEO100开放血脑屏障可促进静脉输注的CD19 CAR T细胞进入脑内,全部中枢神经系统淋巴瘤小鼠长期存活且影像学肿瘤消失,提示该一次性治疗干预可能具有治愈性。
研究设计与样本
- 在人Raji淋巴瘤细胞脑内植入的免疫缺陷小鼠模型中,经生物发光成像确认肿瘤摄取后,动脉内注射0.3% NEO100,随后静脉输注CD19靶向CAR T细胞,单次干预后以影像学监测肿瘤生长并记录长期生存,选取部分小鼠安乐死分析CAR T细胞在脑组织中的分布。
主要发现
- 动脉内注射NEO100后静脉注射的CAR T细胞可于脑肿瘤区域检出,而动脉内注射不含NEO100的溶媒后则未检出。
- 所有未治疗对照动物均在3周内死亡,而接受动脉内NEO100后静脉CAR T细胞的所有小鼠均存活并状态良好至200天实验终止。
- 仅接受静脉CAR T细胞而未预先动脉内注射NEO100的小鼠中,3只在3周内死亡,2只长期存活。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Malignancies of the CNS are difficult to treat because the blood-brain barrier (BBB) prevents most therapeutics from reaching the intracranial lesions at sufficiently high concentrations. This also applies to chimeric antigen receptor (CAR) T cells, for which systemic delivery is inferior to direct intratumoral or intraventricular injection of the cells. The authors previously reported on a novel approach to safely and reversibly open the BBB of mice by applying intra-arterial (IA) injections of NEO100, a pharmaceutical-grade version of the natural monoterpene perillyl alcohol. The authors hypothesized that this method would enable enhanced brain entry and therapeutic activity of intravenously delivered CAR T cells, which the authors tested in a mouse model of CNS lymphoma. METHODS: Human Raji lymphoma cells were implanted into the brains of immune-deficient mice. After tumor uptake was confirmed with bioluminescent imaging, 0.3% NEO100 was injected intra-arterially, which was followed by intravenous (IV) delivery of CD19-targeted CAR T cells. After this single intervention, tumor growth was monitored with imaging, long-term survival of mice was recorded, and select mice were euthanized to analyze the distribution of CAR T cells in brain tissue. RESULTS: Intravenously injected CAR T cells could be readily detected in brain tumor areas after IA injection of NEO100 but not after IA injection of the vehicle (without NEO100). Although all untreated control animals died within 3 weeks, all mice that received IA NEO100 followed by IV CAR T cells survived and thrived for 200 days, when the experiment was terminated. Of the mice that received IV CAR T cells without prior IA NEO100, 3 died within 3 weeks and 2 survived long-term. CONCLUSIONS: BBB opening by IA NEO100 facilitates brain entry of intravenously delivered CD19 CAR T cells. The long-term survival of all mice with CNS lymphoma, along with the disappearance of the tumor as determined with imaging, suggests that this one-time therapeutic intervention was curative. BBB opening by IA NEO100 may offer a novel option to increase brain access by CAR T cells.
引用
- Wang W, He H, Zheng L, et al. Enhancing brain entry and therapeutic activity of chimeric antigen receptor T cells with intra-arterial NEO100 in a mouse model of CNS lymphoma. J Neurosurg. 2023. PMID: 38157532. doi:10.3171/2023.10.JNS231097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。